Platelet hyperaggregability: impaired responsiveness to nitric oxide ("platelet NO resistance") as a therapeutic target

scientific article published on 11 March 2008

Platelet hyperaggregability: impaired responsiveness to nitric oxide ("platelet NO resistance") as a therapeutic target is …
instance of (P31):
review articleQ7318358
scholarly articleQ13442814

External links are
P356DOI10.1007/S10557-008-6098-7
P698PubMed publication ID18327704

P2093author name stringSharmalar Rajendran
Yuliy Y Chirkov
P2860cites workDownregulation of soluble guanylyl cyclase in young and aging spontaneously hypertensive ratsQ33178899
Efficacy and safety of perhexiline maleate in refractory angina. A double-blind placebo-controlled clinical trial of a novel antianginal agentQ37909293
Reduced responsiveness of hypercholesterolemic rabbit aortic smooth muscle cells to nitric oxideQ42436267
Increased secretion of tumor necrosis factor-alpha and interferon-gamma by mononuclear leukocytes in patients with ischemic heart disease. Relevance in superoxide anion generationQ42495904
Active oxygen species play a role in mediating platelet aggregation and cyclic flow variations in severely stenosed and endothelium-injured coronary arteries.Q54040101
L-arginine infusion decreases peripheral arterial resistance and inhibits platelet aggregation in healthy subjects.Q54195872
Effects of L-arginine on impaired acetylcholine-induced and ischemic vasodilation of the forearm in patients with heart failure.Q54198187
Platelet Activation by Superoxide Anion and Hydroxyl Radicals Intrinsically Generated by Platelets That Had Undergone Anoxia and Then ReoxygenatedQ58421352
P433issue3
P304page(s)193-203
P577publication date2008-03-11
P1433published inCardiovascular Drugs and TherapyQ2473050
P1476titlePlatelet hyperaggregability: impaired responsiveness to nitric oxide ("platelet NO resistance") as a therapeutic target
P478volume22

Reverse relations

cites work (P2860)
Q92312063Alterations in platelet bioenergetics in Group 2 PH-HFpEF patients
Q82369273Antiplatelet activity of 3-butyl-6-bromo-1(3H)-isobenzofuranone on rat platelet aggregation
Q91933497Comparative proteomics reveals unexpected quantitative phosphorylation differences linked to platelet activation state
Q90392647Induction of caveolin-3/eNOS complex by nitroxyl (HNO) ameliorates diabetic cardiomyopathy
Q45801323Lack of effect of nitrates on exercise stress test results in patients with microvascular angina
Q37887771Nitric oxide: a guardian for vascular grafts?
Q35141772Oral antiplatelet therapy in diabetes mellitus and the role of prasugrel: an overview
Q37807427Platelet physiology and antiplatelet agents
Q96767385Prolonged suppression of the anti-oxidant/anti-inflammatory effects of BNP post-Takotsubo syndrome
Q27003277The prothrombotic tendency in metabolic syndrome: focus on the potential mechanisms involved in impaired haemostasis and fibrinolytic balance

Search more.